RCS - Crystal Amber Fund - Morphic Medical Inc. appoints new Chief Executive

Crystal Amber FundAnnouncement

05/08/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250805:nRSE9143Ta&default-theme=true

RNS Number : 9143T  Crystal Amber Fund Limited  05 August 2025

REACH - a non-regulatory announcement

5 August 2025

 

Crystal Amber Fund Limited

("Crystal Amber Fund", the "Company" or the "Fund")

 

Morphic Medical Inc. appoints new Chief Executive

 

The Board of Crystal Amber Fund is pleased to announce that Morphic Medical
Inc. ("MMI"), the medical device company that has pioneered minimally invasive
treatments of obesity and cardiometabolic disorders in which it owns 96.7% of
the issued share capital has appointed Mike Gutteridge, most recently MMI's
Commercial Director, as Chief Executive. Mike brings a wealth of experience in
the bariatric endoscopy space.

 

Last month, Crystal Amber announced that MMI had received CE Mark
certification for its revolutionary RESET® therapy, making this the first
endoscopic, non-surgical treatment for both obesity and Type 2 diabetes
in Europe.

This CE designation, which ensures RESET® has met all European
Commission safety, health and environmental protection requirements, allows
access to treatment for the estimated 93 million patients in Europe living
with obesity and type 2 diabetes.

 

After five years and with CE Mark now achieved, Joe Virgilio has stepped down
as Chief Executive.

 

Christopher Waldron, Chairman of Crystal Amber commented: "The Board would
like to thank Joe for delivering CE Mark and for all his efforts and
commitment to innovation and patient care. The Board is excited that Mike, who
brings a successful track record of international commercialisation, will be
leading MMI as it enters a new and exciting stage of growth."

 

Mike Gutteridge commented: "I am honoured to become Chief Executive. With over
thirty years in the MedTech sector spanning clinical innovation, commercial
strategy, market development and reimbursement, I am energised by the
opportunity to lead Morphic into its next phase, a focused expansion into
global markets, accelerated commercialisation, and a deepening of our
commitment to improving the lives of patients through effective durable
therapies. This is an exciting time for our company, and I am proud to help
shape what comes next."

 

 

For further enquiries please contact:

 

Crystal Amber Fund Limited

Chris Waldron (Chairman)

Tel: 01481 742 742

www.crystalamber.com (http://www.crystalamber.com)

 

Allenby Capital Limited - Nominated Adviser

Jeremy Porter/ Dan Dearden-Williams

Tel: 020 3328 5656

 

Winterflood Investment Trusts - Broker

Joe Winkley/Neil Langford

Tel: 020 3100 0160

 

Crystal Amber Advisers (UK) LLP - Investment Adviser

Richard Bernstein

Tel: 020 7478 9080

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for Companies,
Market Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZGGRVDGGKZM